Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Increased to $46.00 by Analysts at Wedbush

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target raised by Wedbush from $43.00 to $46.00 in a research note released on Friday, Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. Wedbush also issued estimates for Ultragenyx Pharmaceutical’s FY2027 earnings at $1.01 EPS and FY2028 earnings at $1.85 EPS.

Other analysts also recently issued reports about the company. Robert W. Baird raised their target price on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an outperform rating in a research note on Friday, May 31st. The Goldman Sachs Group upgraded shares of Ultragenyx Pharmaceutical from a neutral rating to a buy rating and boosted their target price for the company from $56.00 to $67.00 in a report on Thursday, June 6th. TD Cowen raised their price target on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a buy rating in a report on Wednesday, April 24th. Royal Bank of Canada started coverage on Ultragenyx Pharmaceutical in a research report on Monday, April 22nd. They issued an outperform rating and a $77.00 price objective for the company. Finally, Canaccord Genuity Group restated a buy rating and issued a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $87.92.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE opened at $49.08 on Friday. The stock has a 50 day moving average price of $42.00 and a 200 day moving average price of $44.49. The stock has a market capitalization of $4.08 billion, a price-to-earnings ratio of -6.01 and a beta of 0.56. Ultragenyx Pharmaceutical has a one year low of $31.52 and a one year high of $54.56.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.12. The business had revenue of $147.03 million for the quarter, compared to analyst estimates of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 392.36%. The business’s revenue was up 35.7% on a year-over-year basis. During the same period last year, the company posted ($2.25) EPS. On average, analysts predict that Ultragenyx Pharmaceutical will post -6.45 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 9,806 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $441,270.00. Following the sale, the executive vice president now owns 57,981 shares of the company’s stock, valued at $2,609,145. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.10, for a total value of $71,390.70. Following the sale, the director now directly owns 7,248 shares of the company’s stock, valued at approximately $297,892.80. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Karah Herdman Parschauer sold 9,806 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $441,270.00. Following the sale, the executive vice president now directly owns 57,981 shares of the company’s stock, valued at $2,609,145. The disclosure for this sale can be found here. Insiders have sold a total of 12,127 shares of company stock worth $536,593 in the last ninety days. 5.80% of the stock is owned by corporate insiders.

Institutional Trading of Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 1st quarter valued at about $28,000. UMB Bank n.a. boosted its holdings in Ultragenyx Pharmaceutical by 118.8% in the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 329 shares in the last quarter. nVerses Capital LLC purchased a new position in Ultragenyx Pharmaceutical in the second quarter valued at approximately $33,000. GAMMA Investing LLC increased its stake in Ultragenyx Pharmaceutical by 622.3% in the first quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 865 shares during the last quarter. Finally, Van ECK Associates Corp lifted its position in shares of Ultragenyx Pharmaceutical by 34.0% during the 4th quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 400 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.